Verrica Pharmaceuticals (VRCA)

Its lead commercial product is YCANTH, also known as VP-102, a proprietary drug-device combination containing a controlled formulation of cantharidin. YCANTH is approved in the United States for the treatment of molluscum contagiosum in adult and pediatric patients aged two years and older. Molluscum is a contagious viral skin infection that commonly affects children and can cause raised lesions that persist for months. Because YCANTH is administered by healthcare professionals, Verrica’s commercial strategy is closely linked to dermatology practices, pediatric dermatology, reimbursement access, and physician education.

The company’s platform is built around topical, office-based therapies that can be applied in a controlled manner. Beyond molluscum, Verrica has explored additional dermatologic indications for its product candidates, including other viral skin conditions and skin cancers. Its pipeline reflects an effort to build a broader specialty dermatology business rather than rely on a single indication.

For investors, Verrica combines the characteristics of a commercial-stage pharmaceutical company and a clinical development business. Revenue growth depends on YCANTH adoption, payer coverage, supply execution, and the company’s ability to expand awareness among clinicians and patients. At the same time, its long-term value is influenced by pipeline progress, regulatory outcomes, and competition from established dermatology treatments and procedural alternatives.